louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04957407: The Research of Constructing a Risk Assessment Model for Gastric Cancer Based on Machine Learning
Official title: The Research of Constructing a Risk Assessment Model for Gastric Cancer Based on Machine Learning
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Gastric Cancer
Precancerous Lesion
Mechine Learning
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2021-07-12
Enrollment: 5000
Sex: ALL
Minimum age (years): 25
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: consecutive subjects who underwent regular health checkup at nine International Healthcare

Brief summary: Based on the gastric cancer database established earlier, this project explored the PG standard suitable for Chinese people, and further explored the establishment of machine learning model to stratify gastric cancer risk in the population, guide the frequency of gastroscopy screening, and extract important gastric cancer risk factors from it.Establish electronic health records of gastric organs, track the development and outcome of gastric diseases through deep learning method, in order to predict the development and outcome of gastric diseases;Then, the simulation hypothesis deductive method is used to compare the outcomes that may be caused by different lifestyles with the help of deep learning model, so as to guide patients to develop a better lifestyle and explore the establishment of health management paths for gastric cancer patients and high-risk groups in China.


Eligibility criteria: Inclusion Criteria:

* 1） intention to undergo gastroscopy during health checkup examination; and 2) 25-75 years of age

Exclusion Criteria:

* 1) a history of gastric ulcer, gastric polyp, or GC; 2) a history of gastrectomy; 3) treatment with a proton pump inhibitor in the last month; 4) contraindications to gastroscopy; 5) a history of Hp eradication; 6) a history of abdominal pain, abdominal distention, belching, acid reflux, nausea and other digestive tract symptoms within 1 month or 67) incomplete data.

Primary outcomes:
measure: pepsinogen value for precanceous lesion and Gastric cancer
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Zhejiang Provincial Hospital of Traditional Chinese Medicine
city: Ningbo
country: China
facility: Ningbo cadres health center
Study officials:
affiliation: 2nd affiliated hospital of Zhejiang University, school of medicine
name: Yuling Tong, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00353509: Safety and Effectiveness Study of the Solysafe Septal Occluder
Official title: Prospective Mono-center Clinical Study to Evaluate the Safety and Effectiveness of an Intracardiac Septal Closure Device in Patients With Atrial Septum Defect (ASD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Atrial Septal Defects
Lead sponsor: Carag AG
Sponsor class: INDUSTRY
First posted: 2006-07-18
Sex: ALL
Minimum age (years): 2
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Prospective mono-center clinical study to evaluate the safety and effectiveness of an intracardiac septal closure device in patients with atrial septum defect (ASD)


Eligibility criteria: Inclusion Criteria:

* ASD

Exclusion Criteria:

* Criteria that exclude catheterization (e.g. too small size, DIC, high risk of bleeding such as coagulation or clotting disorders)

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Belgrade
country: Serbia
facility: University Childen's Hospital
Study officials:
affiliation: University Children's Hospital Belgrade
name: Ida Jovanovic, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01851109: Prevention of Ovarian Cancer in Women Participating in Mammography
Official title: Prevention of Ovarian Cancer in Women Participating in Mammography
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Epithelial Ovarian Cancer
Keywords: ovarian cancer
prevention
prophylactic surgery
risk
biomarkers
screening
symptoms
Lead sponsor: Fred Hutchinson Cancer Center
Sponsor class: OTHER
Collaborators: name: Swedish Medical Center
First posted: 2013-05-10
Enrollment: 458
Sex: FEMALE
Minimum age (years): 35
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The primary purpose of this study is to evaluate the effect of systematic identification and genetic counseling referral on rates of bilateral salpingo-oophorectomy (surgery to remove both fallopian tubes and ovaries) in women having mammograms at Swedish Medical Center in Seattle, WA.


Eligibility criteria: Inclusion Criteria:

* Prior mammogram at Swedish Medical Center
* Willing and able to provide informed consent, primary physician information, and complete study questionnaires
* Must meet at least ONE of the following criteria:
* personal history of breast cancer diagnosed before age 50
* personal history of bilateral breast cancer at any age
* 1 or more first degree relatives with breast cancer diagnosed before age 50
* 3 or more first or second degree relatives with breast cancer at any age
* 2 second degree relatives with breast cancer diagnosed before age 50
* A male relative with breast cancer at any age
* Ashkenazi Jewish with any family history of breast or ovarian cancer
* 1 first or second degree relative with ovarian cancer AND 1 first or second degree relative with breast cancer at any age
* 2 first degree relatives with ovarian cancer or 2 second degree relatives with ovarian cancer or 1 first and 1 second degree relative with ovarian cancer.
* A first degree relative with both breast and ovarian cancer (2 primaries in the same person)
* Personal history of positive genetic test result for any of the following genes: BRCA1, BRCA2, HNPCC, or P53
* Family history of a positive genetic test result for any of the following genes: BRCA1, BRCA2 or HNPCC

Exclusion Criteria:

* Previous diagnosis of ovarian cancer
* Prior bilateral-salpingo oophorectomy
* Had a negative genetic test result for a known family genetic mutation

Primary outcomes:
measure: Compare rates of risk-reducing salpingo-oophorectomy in each of the study arms
timeFrame: 24 months post-enrollment
Secondary outcomes:
measure: Cancer related distress
timeFrame: change from baseline at 12 and 24 months post-enrollment
measure: Health-related quality of life
timeFrame: change from baseline at 12 and 24 months post-enrollment
Other outcomes:
Locations:
city: Seattle
country: United States
facility: Fred Hutchinson Cancer Research Center
state: Washington
Study officials:
affiliation: Fred Hutchinson Cancer Center
name: Nicole Urban, ScD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00071409: Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes
Official title: A Randomized, Double-blind, Placebo-controlled, Rising Dose, Multicenter Study to Evaluate the Efficacy and Safety of 90 Days of 300 or 600 mg Daily Subcutaneous Injections of INGAP Peptide in Type I Diabetes Mellitus Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Diabetes Mellitus, Insulin-Dependent
Keywords: Type 1 diabetes
Lead sponsor: Exsulin Corporation
Sponsor class: INDUSTRY
First posted: 2003-10-23
Enrollment: 63
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Insulin is a chemical that the body needs in order to use or store sugar. It is made by a type of cell called a beta cell which resides in an organ known as the pancreas. Type 1 diabetes is a disease where the beta cells have been destroyed so that little or no insulin is made. Sugar levels rise in the blood as a result. INGAP-Peptide is being tested to attempt to create new beta cells in the pancreas, and to restore the ability to produce insulin in type 1 diabetic patients.


Eligibility criteria: Inclusion Criteria

* Age 18-65
* fasting C-peptide \<0.3 ng/ml.
* HbA1c \<10%
* history of onset of type 1 DM at or before 20 years of age.
* Otherwise healthy

Primary outcomes:
measure: assess efficacy and safety based on arginine stimulated C peptide, fasting C peptide, average daily insulin dose, fasting glucose, glycosylated hemoglobin (Hb A1c), and AEs
timeFrame: 90 days
Secondary outcomes:
Other outcomes:
Locations:
city: Irvine
country: United States
facility: Radiant Research
state: California
city: San Diego
country: United States
facility: VA Hospital UCSD
state: California
city: Walnut Creek
country: United States
facility: Diablo Clinical Research
state: California
city: Washington
country: United States
facility: MedStar Clinical Research Center
state: District of Columbia
city: Springfield
country: United States
facility: Springfield Diabetes and Endocrine Center
state: Illinois
city: Butte
country: United States
facility: Mercury Street Medical
state: Montana
city: Durham
country: United States
facility: UNC Diabetes Care Center
state: North Carolina
city: Medford
country: United States
facility: Clinical Research Institute of Southern Oregon
state: Oregon
city: San Antonio
country: United States
facility: University of Texas Health Science Center - Texas Diabetes Institute
state: Texas
city: San Antonio
country: United States
facility: DGD Research Associates
state: Texas
Study officials:
References:
Clinical trial NCT01621009: Bupropion SR Plus Counseling for Smoking Cessation
Official title: A Randomized Controlled Clinical Trial of Bupropion SR and Individual Smoking Cessation Counseling
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Tobacco Dependence
Smoking
Keywords: smoking cessation medications
smoking cessation counseling
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
name: National Institute on Drug Abuse (NIDA)
First posted: 2012-06-15
Enrollment: 463
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to determine if bupropion plus counseling was more effective than bupropion alone or counseling alone in helping smokers quit smoking.


Eligibility criteria: Inclusion Criteria:

* Smoke 10 or more cigarettes per day
* Expired carbon monoxide (CO) level greater than 9 parts per million (ppm)
* Motivated to quit smoking (score of 3 on 4-point self-report scale)
* Willing to fulfill study requirements

Exclusion Criteria:

* Carbon monoxide breath test score below 9 ppm
* Serious psychopathology (bipolar disorder, psychosis)
* Center for Epidemiologic Studies Depression Scale CES-D)score over 16
* Contraindications for use of bupropion
* History of seizure disorder
* History of eating disorder
* Current heavy drinking
* Risk of pregnancy
* Current breastfeeding

Primary outcomes:
measure: 7-day Point Prevalence Abstinence From Smoking at 6 Months
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Madison
country: United States
facility: UW Center for Tobacco Research and Intervention
state: Wisconsin
Study officials:
affiliation: University of Wisconsin, Madison
name: Timothy B Baker, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Wisconsin, Madison
name: Timothy B Baker, PhD
role: STUDY_DIRECTOR
References:
citation: McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Fiore MC, Baker TB. A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling. Nicotine Tob Res. 2008 Apr;10(4):717-29. doi: 10.1080/14622200801968343.
Clinical trial NCT03148509: A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward Pathway
Official title: Clinical Psychopharmacology Division Institute of Mental Health, Peking University
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Diagnosis and Treatment of Depression
Lead sponsor: Peking University
Sponsor class: OTHER
First posted: 2017-05-11
Enrollment: 300
Sex: ALL
Minimum age (years): 15
Maximum age (years): 55
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will recruit depressed patients unresponsive to selective serotonin reuptake inhibitor antidepressant treatment, first-degree relatives (parents or siblings) of depressed patients, schizophrenia, Parkinson's disease with and without depression, and healthy controls. The subjects need to complete the brain positron emission tomography/magnetic resonance examination, stress assessment, genetic testing, clinical evaluation and neuropsychological tests. Using the data, this study aimed to identify the abnormalities of reward circuit of depression and its differences with other diseases, and its abnormalities in first-degree relatives of depression. The depressed patients who were ineffective in treatment with selective serotonin reuptake inhibitor antidepressants were then given combined medication with dopamine receptor-mediated drugs, including dopamine transporter inhibitor - bupropion, D2 receptor antagonist - risperidone, or D2 receptor partial agonist - aripiprazole, to examine the regulation of dopamine pathway and its relationship with the therapeutic effect. Through the above work, we will provide new evidence for integrating the biological evidence of dopamine reward pathway into the clinical practice of depression.


Eligibility criteria: Inclusion Criteria:

* patients unresponsive to SSRI antidepressant treatment, first-degree relatives (parents or siblings) of depressed patients, schizophrenia, Parkinson's disease with and without depression, and healthy controls

Exclusion Criteria:

* Major physical illness; other DSM-IV axis I mental illness; personality disorder, mental retardation; drug and/or alcohol dependence; pregnant or lactating women; MRI examination contraindications.

Primary outcomes:
measure: Hamilton Rating Scale for Depression
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02775409: Prospective Trial of Subcutaneous Versus Subpectoral 2-Staged Implant-Based Breast Reconstruction
Official title: Prospective Trial of Subcutaneous Versus Subpectoral 2-Staged Implant-Based Breast Reconstruction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Reconstruction Following Mastectomy
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2016-05-17
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is for women scheduled to have immediate breast reconstruction following mastectomy using a tissue expander. The primary purpose of this study is to learn whether there are differences in the outcome between placing the tissue expander above the muscle or below the muscle. The study will evaluate pain, wellbeing, and overall satisfaction with reconstruction. A secondary purpose is to learn whether there are differences in complications and costs between the two locations.


Eligibility criteria: Inclusion Criteria:

1. Women at least 18 years of age, who will undergo immediate unilateral or bilateral implant-based breast reconstruction following therapeutic skin-sparing or nipple-sparing mastectomy.
2. Women at least 18 years of age, who will undergo immediate bilateral implant-based breast reconstruction following risk-reduction (prophylactic) skin-sparing or nipple-sparing mastectomy.

Exclusion Criteria:

1. Subjects who are unable to read or speak English.
2. Patients desiring autologous reconstruction.
3. BMI \>40.
4. History of radiation therapy to the breast(s), e.g. history of breast conservation therapy.
5. Current nicotine and/or tobacco use.
6. Documented diagnosis of chronic pain.
7. Women who are pregnant or breast-feeding \*
8. Women who decline the use of acellular dermal matrix (ADM).
9. Surgeon decision not to proceed with tissue expander reconstruction.
10. Women undergoing single stage (straight to implant) reconstruction.

Primary outcomes:
measure: Change in patient satisfaction
timeFrame: Baseline, Year 3
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Minh-Doan Nguyen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03313609: Investigating Burnout in Intensive Care in Middle Incoming Turkey
Official title: Investigating Burnout in Intensive Care in Middle Incoming Turkey
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Burnout Syndrome
Lead sponsor: Dr. Ersin Arslan Education and Training Hospital
Sponsor class: OTHER_GOV
First posted: 2017-10-18
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: working intensive care medicine

Brief summary: Turkey is a developing country and its intensive care infrastructure is worse than developed countries. The staff is very busy at work. Intensive care has become a new science. We wanted to investigate burnout syndrome among physicians and other health care workers who are starting to work at a new intensive care medicine. Intensive care specialists in Turkey do not work in intensive care centers where they want. This may have a negative effect on physicians.

Detailed description: Burnuot health practices are more common than the normal group. The data about Turkey are limited. In developing societies, there are often no protocols in intensive care. There are no teams again during intensive care. All work is done by physicians and other health workers. This may adversely affect health care workers. Intensive care science is new. The training first started in 2013. The newly graduated heavy-duty specialists can work where they do not want. The workload of the health workers working in the intensive care unit is high. We wanted to investigate burnout on healthcare workers in Turkey.

Eligibility criteria: Inclusion Criteria:

fellow, nursing, specialist and academics working intensive care medicine

Exclusion Criteria:

Primary outcomes:
measure: maslach burnout inventory measure
timeFrame: 20 day
Secondary outcomes:
Other outcomes:
Locations:
city: Gaziantep
country: Turkey
facility: Dr. Ersin Arslan Education and Training Hospital
Study officials:
References:
Clinical trial NCT01618409: PictureRx: An Intervention to Reduce Latino Health Disparities
Official title: PictureRx: An Intervention to Reduce Latino Health Disparities
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Medication Adherence
Diabetes
Keywords: PictureRx
Health Literacy
Limited English Proficiency
Latinos
Spanish
Lead sponsor: PictureRx, LLC
Sponsor class: OTHER
Collaborators: name: National Institute on Minority Health and Health Disparities (NIMHD)
First posted: 2012-06-13
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this randomized controlled trial is to evaluate the effect of Spanish-language illustrated medication instructions (PictureRx cards), compared to traditional medication instructions, on Latinos' understanding of their medication regimens. The study will also assess the effect on self-reported medication adherence. Patients with diabetes who attend participating clinics are eligible. The target sample size is 200.


Eligibility criteria: Inclusion Criteria:

* Diabetes
* Latino, Spanish speaker
* Be at least 18 years old
* Must be taking at least 1 chronic medication

Exclusion Criteria:

* Too ill to participate in an interview
* Do not have a telephone
* Having visual acuity worse than 20/50 via Rosenbaum Visual Acuity exam (eyechart)
* Inability to communicate in either Spanish or English
* Overt psychiatric illnesses, overt delirium or dementia

Primary outcomes:
measure: Patient Understanding of their Medication Regimen
timeFrame: Approximately 1 week after enrollment
Secondary outcomes:
measure: Self-reported Adherence
timeFrame: Approximately 1 week after enrollment
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Saint Thomas Family Health Center - South
state: Tennessee
Study officials:
affiliation: PictureRx, LLC
name: M Brian Riley, MA
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01376609: The Correlation Between Outcome and Infarct Growth in Patients With Acute Ischemic Stroke
Official title: A MRI-based Study of Ischaemic Penumbra: the Correlation Between Outcome and Infarct Growth in Patients With Acute Ischemic Stroke
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Ischemic Stroke
Keywords: Stroke
Ischaemic Stroke
Cerebral Infarction
Cerebrovascular Disorders
Brain Diseases
Nervous System Diseases
Vascular Diseases
Brain Infarction
Brain Ischemia
mismatch
PWI/DWI mismatch
ischaemic penumbra
image analysis
Lead sponsor: Beijing Hospital of Traditional Chinese Medicine
Sponsor class: OTHER
Collaborators: name: Beijing University of Chinese Medicine
First posted: 2011-06-20
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with acute ischaemic stroke admitted to ASU.

Brief summary: Previous research has shown there wasn't inevitable relationship between mismatch area and infarct growth according to Volumetric-subtraction mismatch volume.The recently published on Stroke paper has proposed Coregistration mismatch to calculate the mismatch to replace ischaemic penumbra, and it reignites hope for clinical application of the PWI/DWI mismatch. But the correlation between the mismatch, calculated by Coregistration mismatch method,and the clinical outcome of the patients with acute ischemic stroke is still unknown. so the investigators plan to conduct a prospective observational cohort study.

Detailed description: NIHSS,mRS and MR PWI/DWI/MRA are performed within 48 hours of stroke onset and final MR T2/flair image at ≈1 month. And then,Volumetric-subtraction mismatch and Coregistered mismatch will be calculated,respectively.finally,we will assess and compare the Volumetric-subtraction mismatch and Coregistered mismatch, and to clarify which method match the clinical outcome more better.

Eligibility criteria: Inclusion Criteria:

* Aged eighteen or above
* Acute middle cerebral artery ischemic stroke
* Stroke onset within 48 hours
* Included a complete set of initial MR images and final outcome MR images up to 1 months

Exclusion Criteria:

* History of stroke in the past 6 weeks
* Pre-existing neurological or psychiatric disease that could confound the study results such as a pre-stroke mRS score greater than 3
* CT evidence of the following conditions before enrollment:

Significant mass effect with midline shift Evidence of intracranial hemorrhage

* With contraindication to MR such as severe allergy to contrast media

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Jianghai Ruan
state: Beijing
Study officials:
References: